PI3K/Akt/mTOR信号通路在非小细胞肺癌中作用的研究进展

肺癌是当今世界上严重威胁人类健康与生命的恶性肿瘤,每年有超过100万人死于肺癌。PI3K/Akt通路在肿瘤治疗方面已经有了比较广泛的研究,活化受体酪氨酸激酶和它们下游信号递质的研究也已经为肺癌的治疗打开了一个非常有前景的领域。由于PI3K/Akt通路在下游多点活化受体酪氨酸激酶,因此被广泛地研究并开发新的抗肿瘤制剂。mTOR已经被确定是PI3K/Akt的下游靶点。雷帕霉素及其衍生物具有高度选择性,mTOR的抑制剂对于多种肿瘤的治疗效果已取得了很好的研究结果。在此我们将对肺癌中PI3K/Akt/mTOR信号通路的分子基础做一综述,并进一步讨论有关肺癌的多靶点治疗策略。

Function of PI3K/Akt/mTOR Pathway in Non - small Cell Lung Cancer

Lung cancer is a malignant tumor threatening human health and life,with more than 1 million deaths per year in the world.PI3K/Akt pathways have been extensively studied in neoplasia.Furthermore,the study of activated receptor tyrosine kinases(RTKs)and their downstream signaling mediators has opened a promising new field of lung cancer treatment.Since PI3K/Akt pathways are downstream of activated RTKs,they have been extensively studied for the development of novel anti-tumor agents.Moreover,mTOR has been identified as a downstream target of the PI3K/Akt pathway.Rapamycin and its derivatives are highly selective inhibitors of mTOR,reported encouraging results for different tumor types.But for lung cancer,there are not clear reports.Here we will review the molecular basis of PI3K/Akt/mTOR pathway in lung cancer and further discuss the therapeutic potential of multi-targeted strategies.